chartexchange

SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET

GlobeNewswire Inc. | Oct 29, 2026 8:30 AM EDT

MIAMI, Oct. 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS ), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its third quarter 2026 financial results will be issued on the morning of Thursday, November 5, 2026. Management will host a conference call and webcast at 08:30 AM ET to discuss the results and provide business updates.

Read original article